the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs
December 16, 2015 – This post is somewhat delayed; however, it may still be of interest for some readers of thasso post and therefore, the information is provided here uncommented, as it was issued by both the FDA and the EMA …
December 5, 2015 – A safety review by the American Food and Drug Administration (FDA) has resulted in the addition of specific warnings to the drug labels of a specific class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors …
December 02, 2015 – The American Food and Drug Administration (FDA) just granted approval for Elotuzumab (Empliciti) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications. Elotuzumab (Empliciti) is a monoclonal …
November 28, 2015 – The American Food and Drug Administration (FDA) just approved Necitumumab (Portrazza) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication …
November 21, 2015 – During the last few days, the American Food and Drug Administration (FDA) just extended the armamentarium in the fight against multiple myeloma by two new entries, namely Ixazomib (Ninlaro) and Daratumumab (Darzalex). Both drugs are intended to treat …
November 14, 2015 – The American Food and Drug Administration (FDA) just granted accelerated approval for an oral medication to treat patients with advanced non-small cell lung cancer (NSCLC). Osimertinib (Tagrisso) was approved for patients whose tumors have a specific …
November 13, 2015 – The American Food and Drug Administration (FDA) just approved Cobimetinib (Cotellic) to be used in combination with Vemurafenib (Zelboraf) to treat advanced melanoma that has spread to other parts of the body or can’t be removed by …
November 06, 2015 – Just about the same time at the End of October 2015, the American Drug and Food Administration (FDA) has approved, and the European Medicines Agency (EMA) has recommended for approval Talimogene Laherparepvec (Imlygic), a first-in-class advanced therapy medicinal product (ATMP) derived from a …
Imlygic, a first-of-its-kind oncolytic immunotherapy for the treatment of melanoma Read more »
October 28, 2015 – According to a small prospective and randomized clinical study, just published online in the Annals of Internal Medicine, a regularly taken glass of wine with dinner may improve lipid and glycemic control profiles in patients with type 2 …
October 11, 2015 – In recent months, Nivolumab (Opdivo), a human IgG4 anti-PD-1 monoclonal antibody which targets the PD-1 receptor, had been approved first for the treatment of unresectable or advanced (metastatic) melanoma and secondly for the treatment of advanced (metastatic) squamous non-small cell …